Fortress Biotech, Inc. (FBIO)

Every figure this model derived for FBIO, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PaymentsToAcquireProductiveAssets 2025-06-30
cash 196,576,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 245,506,000 AssetsCurrent 2026-06-30
current liabilities 62,018,000 LiabilitiesCurrent 2026-06-30
equity 164,140,000 StockholdersEquity 2026-06-30
interest expense 9,627,000 InterestExpenseDebt 2026-06-30
ocf 125,920,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 68,466,000 Revenues 2026-06-30
sbc 10,291,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up FBIO on one particular measure came for.

RatioValue
cash operating margin-27.27
current ratio3.96
current ratio reported3.96
deferred revenue growth-73.11
dilution pct34.27
fcf margin183.92
growth cv2.59
interest cover-3.05
operating margin-42.86
owner earnings margin168.89
revenue growth15.46
revenue growth per share-14.01
roic-904.16
rule of 40-27.41
sbc pct revenue15.03

What to be careful about

What this model itself distrusts about FBIO's figures. Written by the derivation as it ran, not added afterwards.